• 文档语言：英文
• 文档大小：77KB
• 文档类型：PPT
• 发布时间：2017/6/9 14:45:04
• 相关网站：internet
• 下载
• 版权说明：本站所有资源来源于网络，版权为原作者所有，本站刊载，仅限于促进医药行业发展、科技进步之目的。如本站行为侵犯了您的合法权益，请来信告知，我们将妥善处理。给您带来不便，敬请原谅。
• 幻灯介绍：

European trial on reduction of cardiac events with perindopril in stable coronary artery disease
Presented at
European Society of Cardiology 2003
EUROPA Trial
Perindopril
 8 mg/day
 n=6,110
Placebo
 n= 6,108
Endpoints (follow-up mean 3.4 years):
Primary – Composite of CV mortality, nonfatal MI, and cardiac arrest
Secondary – Composite of total death, nonfatal MI, and cardiac arrest; heart failure; revascularization (PCI/CABG); and stroke
EUROPA Trial
European Society of Cardiology 2003
12,218 low-risk patients with stable coronary artery disease
Randomized, double-blind, placebo-controlled
EUROPA Trial
CV death/non-fatal MI/
cardiac arrest
p=0.0003
European Society of Cardiology 2003
CV Mortality
p=0.107
EUROPA Trial
 Among patients with stable coronary artery disease, treatment with the ACE-I perindopril was associated with a reduction in the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest compared with placebo
 ACE inhibitors have previously been shown to be effective in other patient populations, including heart failure, left ventricular dysfunction, and high-risk coronary artery disease patients
 The present trial is the largest to show a benefit in stable, low-risk CAD patients